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The amygdala is intimately involved in emotional behavior, and
its role in the generation of anxiety and conditioned fear is well
known. Benzodiazepines, which are commonly used for the
relief of anxiety, are thought to act by enhancing the action of
the inhibitory transmitter GABA. We have examined the prop-
erties of GABA-mediated inhibition in the amygdala. Whole-cell
recordings were made from neurons in the lateral division of the
central amygdala. Application of GABA evoked a current that
reversed at the chloride equilibrium potential. Application of the
GABA antagonists bicuculline or SR95531 inhibited the GABA-
evoked current in a manner consistent with two binding sites.
Stimulation of afferents to neurons in the central amygdala
evoked an IPSC that was mediated by the release of GABA. The
GABAA receptor antagonists bicuculline and picrotoxin failed to
completely block the IPSC. The bicuculline-resistant IPSC was
chloride-selective and was unaffected by GABAB-receptor an-
tagonists. Furthermore, this current was insensitive to modula-
tion by general anesthetics or barbiturates. In contrast to their
actions at GABAA receptors, diazepam and flurazepam inhib-
ited the bicuculline-resistant IPSC in a concentration-
dependent manner. These effects were fully antagonized by the
benzodiazepine site antagonist Ro15–1788. We conclude that a
new type of ionotropic GABA receptor mediates fast inhibitory
transmission in the central amygdala. This receptor may be a
potential target for the development of new therapeutic strate-
gies for anxiety disorders.
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GABA is the major inhibitory transmitter in the mammalian CNS
(Nicoll et al., 1989). As with many other types of receptor, two
broad types of GABA receptor are recognized: ionotropic ligand-
gated channels and metabotropic G-protein-coupled receptors.
Ionotropic GABA receptors are further subdivided into the
bicuculline-sensitive GABAA receptors (MacDonald and Olsen,
1994; Johnston, 1996a) and the bicuculline-insensitive GABAC
receptors (Qian and Dowling, 1994; Bormann and Feigenspan,
1995). GABAA receptors gate a chloride ionophore and have
modulatory binding sites for benzodiazepines, barbiturates, and
anesthetics, all of which potentiate the response to GABA (Mac-
Donald and Olsen, 1994; Johnston, 1996a). These receptors are
potently inhibited by the competitive antagonists bicuculline and
SR95531 and the plant alkaloid picrotoxin (Sieghart, 1995).
GABAA receptors are assembled from a large family of which
fifteen members have so far been identified: 6a, 4b, 3g, 1d, and 1e
(Barnard et al., 1998). Heterologous expression of different sub-
units has shown that functional GABA receptors can form as
homomers or as heteromultimers of different subunits. However,
most GABAA receptors in the CNS are thought to contain both
a and b subunits, with one or more of the g, d, or e subunits
(Barnard et al., 1998). The subunit combination of a particular
GABA receptor determines its pharmacological properties (Cos-
ta, 1998; MacDonald and Olsen, 1994). For example, amplifica-
tion of GABA action by benzodiazepines is only seen in receptors
that contain one of a1, a2, a5 subunits and either a g2 or a g3
subunit. Receptors that contain a4, a6, or g1 are unaffected by
benzodiazepines (MacDonald and Olsen, 1994; Costa, 1998).
GABAC receptors also gate a chloride channel, but they are not
blocked by bicuculline or SR95531, and are markedly less sensi-
tive to picrotoxin. They are also insensitive to modulation by
benzodiazepines and barbiturates (Qian and Dowling, 1993; Bor-
mann and Feigenspan, 1995; Johnston, 1996b). GABAC receptors
are assembled from r subunits (r1, r2, r3), which share some
homology with GABAA receptor subunits, but do not appear to
coassemble with them. GABAC receptors have only clearly been
demonstrated in the retina (Qian and Dowling, 1994; Enz et al.,
1995). Bicuculline-resistant responses to GABA have been re-
ported in several brain regions (Drew et al., 1984; Arakawa and
Okada, 1988; Strata and Cherubini, 1994). However, the impor-
tance of these receptors outside of the retina has yet to be
demonstrated.
The amygdala is intimately involved in emotional behavior, and
its role in the generation of anxiety and conditioned fear is well
known (Kluver and Bucy, 1939; LeDoux, 1995). Benzodiaz-
epines, which are commonly used for the relief of anxiety, are
thought to produce their therapeutic effect by enhancing the
action of GABA (Tallman and Gallager, 1985; Costa and
Guidotti, 1996). The action of benzodiazepines on GABA recep-
tors within the amygdala is likely to be responsible for the anti-
anxiety action of these agents because binding sites for benzodi-
azepines are present in the amygdala at high density (Niehoff and
Kuhar, 1983; Richards and Mo¨hler, 1984). In this study we have
examined the properties of ionotropic GABA receptors in the
central amygdala. We find that neurons in the central amygdala
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express two types of ionotropic GABA receptor. One is the well
known GABAA type, which is blocked by bicuculline and is
typically modulated by benzodiazepines, barbiturates, and anes-
thetics. The other type is relatively resistant to bicuculline and
picrotoxin, and like GABAC receptors is not modulated by bar-
biturates and anesthetics. However, unlike GABAC receptors,
these bicuculline-resistant GABA receptors are inhibited by ben-
zodiazepines. Both receptor types contribute to fast inhibitory
transmission in the central amygdala.
MATERIALS AND METHODS
All experiments were done on acute brain slices maintained in vitro. All
procedures were in accordance with the Institutional Animal Care and
Ethics Committee guidelines. Wistar rats (17- to 20-d-old) were anesthe-
tized with intraperitoneal pentobarbitone (50 mg/kg), and coronal brain
slices (400 mM) were prepared using standard methods. Slices were
superfused at 200 ml/hr with oxygenated Ringer’s solution containing (in
mM) NaCl 118, KCl 2.5, NaHCO3 25, glucose 10, NaH2PO4 1.2, MgCl2
1.3, and CaCl2 2.5, in a bath volume of 1 ml. Kynurenic acid (2 mM) or
CNQX (10 mM) and D-APV (30 mM) were included in the external
solution to block glutamatergic receptors. In other experiments (our
unpublished observations), we have confirmed that at these concentra-
tions these compounds completely block glutamatergic synaptic transmis-
sion. Tetrodotoxin (0.5 mM) was added to the Ringer’s solution to block
synaptic transmission during experiments with iontophoretically applied
GABA. Whole-cell recordings were made from neurons in the lateral
division of the central amygdala (CeL) or from pyramidal neurons in the
CA1 region of the hippocampus using the “blind” approach. Borosilicate
glass electrodes (3–5 MV) were filled with a cesium-based internal
solution to eliminate the effects of GABAB receptors. The solution was
either high-chloride, containing (in mM) CsCl 130, MgCl2 1, EGTA 10,
HEPES 10, Mg2ATP 2, and Na3GTP 0.2 (pH 7.3 with CsOH, 290
mOsm), or low-chloride, containing (in mM) cesium gluconate 107.5,
CsCl 17.5, NaCl 8, HEPES 10, BAPTA 10, Mg2ATP 2, and Na3GTP 0.2
(pH 7.3 with CsOH, 290 mOsm). Membrane potentials recorded were
corrected for a junction potential of 117 and 210 mV for the high-
chloride and low-chloride internals, respectively. Normalized I–V rela-
tions were constructed by normalizing the current measured at a holding
potential of 280 mV. IPSCs were evoked electrically using stainless steel
bipolar stimulating electrodes (Frederick Haer) placed near the lateral
border of the CeL or near stratum pyramidale in the CA1 region of the
hippocampus. Stimuli were 10–30 V in amplitude and 50 msec in dura-
tion. Iontophoresis pipettes (.5 MV) were filled with either 300 mM
GABA (pH 3) or 300 mM glycine (pH 3) and placed adjacent to recorded
neurons in CeL. Negative retention current (50–100 nA) and positive
ejection current (100–200 nA; 0.1–1 sec duration) were generated by a
Dagan 6400 iontophoresis unit. Signals were filtered (5 kHz) and ampli-
fied using an Axopatch 1D amplifier (Axon Instruments, Foster City,
CA), digitized at 10 kHz (Instrutech, ITC 16), and recorded and ana-
lyzed using Axograph 4.0 software (Axon Instruments) on a Macintosh
computer. Series resistance (5–30 MV) was monitored online throughout
the experiment, and experiments were rejected if resistance changed by
.10%. No series resistance compensation was used.
All values are expressed as mean 6 SEM, and all statistical compar-
isons were done using Student’s t test. Drugs used were CNQX (Tocris
Cookson), bicuculline methiodide, D-APV, propofol (Research Bio-
chemicals, Natick, MA), kynurenic acid, picrotoxin (Sigma, St. Louis,
MO), tetrodotoxin (Alamone Laboratories, Jerusalem, Israel), diaze-
pam (a gift from Prof. P. Gage), 1,2,5,6-tetrohydropyridine-4-
yl)methylphosphinic acid (TPMPA), flurazepam, Ro 15–1788 (gifts
from Associate Prof. G. A. R. Johnston), and pentobarbitone (Bomac
Laboratories).
RESULTS
Whole-cell recordings were made from neurons in the CeL.
Iontophoretic application of GABA evoked a current that re-
versed at the chloride equilibrium potential (Fig. 1A,B). Bath
application of the competitive GABAA receptor antagonist bicu-
culline methiodide (BIC) blocked the GABA-activated current in
a manner that was best fit assuming two binding sites with IC50
values of 0.12 and 23.1 mM (Fig. 1C). Similar results were also
obtained with another competitive GABAA antagonist SR95531
Figure 1. GABA activates two types of
ionotropic receptors in the central amyg-
dala. A, Responses to iontophoretically
applied GABA in a CeL neuron at mem-
brane potential of 280, 260, 240, 220, 0,
and 110 mV using low-chloride internal
solution. B, The current–voltage relation-
ship for the records shown in A ( filled
circles) and responses similarly recorded
from a different cell using high-chloride
internal solution (open squares). The re-
versal potential in low-chloride internal
was 250 mV, whereas in high internal
chloride, it was 22 mV, showing that the
GABA activates a chloride-selective cur-
rent. C, Average responses to ionto-
phoretically applied GABA, recorded in
increasing concentrations of bicuculline.
The graph below plots the percentage in-
hibition of the GABA response for each
dose of bicuculline (n 5 3–6 for each
concentration point, except 0.2 mM, where
n 5 2). The solid line is a fit to the equa-
tion a/(1 1 (IC50 /c)
2) 1 b/(1 1 (IC50 /c))
with IC50 values of 0.12 and 23.1 mM (a 1
b was constrained to equal 1). D, Inhibi-
tion curve for antagonism of the response
to iontophoretically applied strychnine
(n 5 2–6 for each concentration point).
The solid line is a fit to the equation 1/(1 1
(IC50 /c)) with an IC50 of 0.079 mM. E,
Summary of inhibition of the response to
GABA at bicuculline concentrations of 10
and 100 mM (n 5 11), SR95531 at 1 and 10
mM (n 5 3), and strychnine (1 mM; n 5 3).
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(Hamann et al., 1988). On average, 10 mM BIC blocked the
GABA-activated current by 65 6 6%, and 100 mM by 92 6 3%
(n 5 11; Fig. 1E); 1 and 10 mM SR95531 blocked the iontophoretic
current by 77 6 6 and 93 6 6% (n 5 3), respectively. These
results suggest that two types of ionotropic GABA receptor are
present on CeL neurons. To rule out the possibility that the low
sensitivity of the GABA response might be caused by inadequate
access of the bath-applied antagonists to their site of action, we
examined a block of iontophoretically applied glycine by the
selective antagonist strychnine. Glycine activated a chloride-
mediated current in all cells tested (data not shown). Strychnine
blocked this current at a single, high-affinity site with an IC50 of
79 nM (Fig. 1D), close to the reported IC50 for strychnine in
isolated cells and membrane patches (Shirasaki et al., 1991; Jonas
et al., 1998). At 10 mM BIC, the contribution of the high-affinity
BIC sites to the GABA response will be negligible. We therefore
used this concentration of BIC to examine the properties of the
BIC-resistant GABA response.
The relative insensitivity of the GABA response to BIC and
SR95531 suggests that a GABAC like receptor might be present.
GABAC receptors can be blocked by high concentrations of
picrotoxin (Polenzani et al., 1991) and the selective antagonist
TPMPA (Ragozzino et al., 1996). In confirmation of this, we
found that the GABA response resistant to BIC was blocked by
88 6 1% by 100 mM picrotoxin (n 5 3) and by 73 6 1% by 60 mM
TPMPA (n 5 3; Fig. 2). These results show that iontophoretically
applied GABA activates two pharmacologically distinct recep-
tors. One has a high affinity for BIC and SR95531, and represents
activation of GABAA receptors, the other is relatively resistant to
BIC and SR95531 but is antagonized by TPMPA.
We next asked if these two types of GABA receptor were also
activated by synaptically released GABA. Stimulation of local
afferents in the presence of glutamatergic antagonists evoked an
IPSC that reversed near the chloride equilibrium potential (Fig.
3A,B), showing that it is a chloride-selective current. Application
Figure 3. GABAergic inhibitory synaptic
currents in the central amygdala are not
blocked by low doses of bicuculline or
picrotoxin. A, Synaptic currents in re-
sponse to local electrical stimulation in
the presence of blockers of glutamatergic
receptors (see Materials and Methods) re-
corded at membrane potentials of 280,
260, 240, 220, 0, and 10 mV using low-
chloride internal solution. B, Normalized
current–voltage relationships for synaptic
currents recorded using low-chloride
(closed circles) (n 5 4) and high-chloride
internal solutions (open squares) (n 5 2).
The reversal potential in low-chloride in-
ternal was 252 mV, whereas in high-
internal chloride it was 0 mV. C, Average
CeL IPSCs recorded in control, in 10 mM
bicuculline, and in 100 mM bicuculline.
The IPSC was blocked to 67 6 3% of
control by 10 mM and 87 6 3% in 100 mM
BIC. D, IPSCs recorded in control, in 25
mM picrotoxin (PTX ), and 100 mM PTX.
IPSC amplitude was blocked by 64 6 0%
in 25 mM PTX. E, Summary of effects of
antagonists bicuculline and picrotoxin on
IPSC peak amplitude recorded from CeL
neurons ( filled columns) or from CA1 py-
ramidal neurons (open columns) (n 5 5, 3,
3, 7, 5, and 4, respectively).
Figure 2. GABAC-like receptors are present in the central amygdala. A,
Responses to iontophoretically applied GABA recorded in control, 10 mM
bicuculline, and 100 mM picrotoxin. B, The trace on the lef t is the response
to iontophoretically applied GABA in the presence of 10 mM BIC. This
current is blocked by application of the selective GABAC antagonist
TPMPA (60 mM). C, Summary data showing the average reduction of the
BIC-resistant response by picrotoxin and TPMPA.
9700 J. Neurosci., November 15, 1999, 19(22):9698–9704 Delaney and Sah • GABA Receptors in Central Amygdala
of bicuculline at a concentration that abolishes inhibitory trans-
mission at GABAA synapses (10 mM) (Jonas et al., 1998) only
reduced IPSC amplitude to 67 6 3% of the control response (n 5
19; Fig. 3C,E). Raising the concentration of BIC to 100 mM
further blocked the IPSC to 87 6 3% (n 5 4) of control. Another
GABAA antagonist picrotoxin was also ineffective in blocking the
IPSC; 25 mM picrotoxin reduced IPSC amplitude to 63.6 6 9.1%
of control (n 5 3), and 100 mM picrotoxin reduced it to 96.7 6
0.5% (n 5 7; Fig. 3D). For comparison, GABAA receptor-
mediated IPSCs recorded in the CA1 region of the hippocampus
were inhibited by 98.3 6 0.6% (n 5 5) in 10 mM BIC and by 99.1 6
0.3% (n 5 4) with 25 mM picrotoxin (Fig. 3E). Thus in the central
amygdala, a component of the inhibitory synaptic current is
resistant to block by bicuculline and picrotoxin.
The BIC-resistant IPSC was a chloride-selective current as it
reversed near the chloride equilibrium potential (Fig. 4A,B). It
was unaffected by the glycine receptor antagonist strychnine (1
mM; n 5 3) or the GABAB antagonist CGP58854 (20 mM; n 5 3).
Application of the GABA uptake inhibitor NO711 (n 5 3) slowed
its decay (Fig. 4C), confirming that it is mediated by the release of
GABA. Thus, as with iontophoretic application of the GABA, a
component of the current activated by synaptically released
GABA is resistant to blockade by BIC and picrotoxin.
We next tested if the BIC-resistant IPSC was caused by acti-
vation of GABAC receptors. TPMPA reversibly inhibited the
BIC-resistant IPSC (Fig. 5A,B) in a dose-dependent manner with
an IC50 of 18 mM (n 5 5). Consistent with previous results
(Ragozzino et al., 1996) the GABAA-receptor IPSC recorded in
area CA1 was unaffected by 60 mM TPMPA (Fig. 5B; n 5 7).
Because GABAC receptors are relatively insensitive to barbitu-
rates, anesthetics, and benzodiazepines we next tested the actions
of these agents on the BIC-resistant IPSC. In each case, we
compared the action of these agents on the BIC-resistant IPSC
with their effects on the GABAA-mediated IPSC recorded from
pyramidal neurons in the CA1 region of the hippocampus. Propo-
fol, an intravenous anesthetic agent that enhances GABAA re-
ceptor responses (Manuel and Davies, 1998) increased the half-
width of the GABAA IPSC by 137 6 22% (n 5 3; p , 0.05) with
little effect on the peak amplitude. In contrast, propofol had no
significant effect on either the peak amplitude or the half width of
the BIC-resistant IPSC in the CeL (n 5 3; Fig. 5C,D). The
barbiturate pentobarbitone also had a reduced effect on the
BIC-resistant IPSC. Pentobarbitone (25 mM) increased the half
width of GABAA-receptor mediated IPSCs by 166 6 29% (n 5
4; p , 0.001) with no change in amplitude. In contrast, neither the
amplitude nor the half-width of the BIC-resistant IPSC were
significantly affected by pentobarbitone. Peak amplitude was re-
Figure 4. A, Synaptic currents recorded in the presence of 10 mM bicu-
culline at membrane potentials of 260, 240, 220, 0, and 110 mV using
low-chloride internal solution. B, Normalized current–voltage relation-
ship for IPSCs recorded in 10 mM bicuculline using low-chloride (closed
circles) (n 5 4) and high-chloride internal solutions (open squares) (n 5 6).
The reversal potential in low-chloride internal was 244 mV, whereas in
high-internal chloride it was 0 mV. C, The GABA uptake blocker NO-711
slows the decay of IPSCs. Each panel shows a train of five IPSCs at
stimulated at 20 Hz. Application of NO-711 slows the decay of the
synaptic current; after washout of NO-711, the decay returns back to the
control response.
Figure 5. GABAC receptors are insensi-
tive to general anesthetics and barbitu-
rates. A, The IPSCs recorded in the pres-
ence of 10 mM bicuculline are reversibly
blocked by TPMPA (60 mM). B, Summary
data for the effect of TPMPA on IPSCs
recorded from neurons the CeL and at
GABAA synapses recorded in pyramidal
neurons in the CA1 region of the hip-
pocampus. TPMPA (60 mM) reduced the
IPSC in the CeL by 65 6 8% (n 5 6), but
had no effect on IPSCs in area CA1 (3 6
4%; n 5 7). C, D, Propofol (10 mM) slowed
the decay of IPSCs in area CA1 (137 6
22%; n 5 3) with no effect on peak am-
plitude, but had no effect on BIC-resistant
IPSCs in the CeL. Traces recorded in the
presence of propofol are indicated by an
asterisk. E, F, Pentobarbitone (25 mM) pro-
longed the decay of IPSCs in area CA1
(half decay 166 6 29% of control; n 5 4)
while having relatively little effect on BIC
IPSCs in the CeL (half decay 32 6 29%
of control; n 5 4). Traces recorded in the
presence of pentobarbitone are indicated
by an asterisk.
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duced by 21.2 6 7.4% ( p 5 0.16), and half-width increased by
32 6 16% (n 5 3; p 5 0.07; Fig. 5E,F).
The 1,4-benzodiazepines act as positive modulators of some
GABAA receptors (MacDonald and Olsen, 1994; Costa, 1998) by
increasing the affinity of the receptor for GABA (Lavoie and
Twyman, 1996), whereas GABAC receptors are insensitive to
these agents. In the CeL, flurazepam (1 mM) reduced the ampli-
tude of the BIC-resistant IPSC by 37 6 5% (n 5 9; Fig. 6A).
Diazepam (1 mM), another 1,4 benzodiazepine, reduced the am-
plitude of the BIC-resistant IPSC by 28 6 7%, and 10 mM
diazepam reduced it by 42 6 5% (n 5 5; Fig. 6C). This effect was
fully antagonized by the benzodiazepine receptor antagonist Ro
15–1788 (Hunkeler et al., 1981) (Fig. 6C), showing that it was not
a nonspecific action of these benzodiazepines. There was no
effect on the kinetics of the IPSC with either diazepam or
flurazepam (Fig. 6A,C). To confirm that the effects of the ben-
zodiazepines on IPSC amplitude were caused by their postsyn-
aptic actions on GABA receptors, we tested the action of diaze-
pam on iotophoretically applied GABA. Diazepam (10 mM)
reduced the amplitude of the BIC-resistant GABA-evoked cur-
rent by 27 6 8% (n 5 5; Fig. 6D), showing that the effects of
diazepam are postsynaptic.
We performed two control experiments to ensure that the
benzodiazepines were active at GABAA receptors in our hands.
First, we checked the action of these drugs on GABAA synapses
recorded from CA1 neurons in the hippocampus. Diazepam (1
mM) increased the amplitude of hippocampal GABAA receptor-
mediated IPSCs by 34 6 16% and its half decay by 17 6 12%
(n 5 5), and at 10 mM, the IPSC amplitude and half width
increased by 41 6 16 and 28 6 18%, respectively (data not
shown). These effects are typical of the actions of benzodiaz-
epines at GABAA synapses (Otis and Mody, 1992; Zhang et al.,
1993). Second, we isolated the GABAA-mediated IPSC in CeL
neurons by performing experiments in the presence of TPMPA.
TPMPA (60 mM) blocked the control IPSC by 27 6 2% (n 5 4).
In the presence of TPMPA, bicuculline (10 mM) blocked the IPSC
(96 6 1% of control; Fig. 7A), confirming it was caused by
activation of GABAA receptors. Application of flurazepam in the
presence of TPMPA had no effect on the peak amplitude but
increased the half width of the IPSC by 121 6 5% (n 5 3; Fig.
7B), showing that GABAA receptors that contribute to the IPSC
have a typical pharmacology.
DISCUSSION
We have shown that in the CeL, both exogenously applied GABA
and synaptically released GABA activate two types of ionotropic
GABA receptor. One is a classical GABAA receptor, inhibited by
BIC and positively modulated by benzodiazepines. The other is
relatively insensitive to the classical GABAA receptor antagonists
bicuculline and picrotoxin. This BIC-insensitive response is
blocked by the GABAC antagonist TPMPA. Furthermore, like
GABAC receptors, the BIC-insensitive component is not affected
Figure 6. Diazepam and flurazepam in-
hibit GABAC receptors in the central
amygdala. A, The effect of flurazepam on
the BIC-resistant IPSC. Flurazepam (1
mM) reduced the peak amplitude (37 6
5% of control; n 5 9) with no effect on the
kinetics of the current. B, The benzodiaz-
epine site antagonist Ro15–1788 (1 mM)
has no effect on IPSC amplitude but
blocks the inhibitory effect of flurazepam.
After washout of Ro15–1788, a second
application of flurazepam now inhibits the
IPSC. Individual records taken from the
times indicated are shown above. C, Sum-
mary data showing the effects of fluraz-
epam and diazepam on BIC-resistant
IPSCs in control conditions (n 5 9) and
Ro 15–1788 (n 5 3). D, The effects of
benzodiazepines are postsynaptic because
diazepam (10 mM) blocks the bicuculline-
resistant response to iontophoretically ap-
plied GABA by 27 6 8% (n 5 5).
Figure 7. Pharmacology of GABAA receptors in the CeL. GABAA
receptors were isolated by blocking GABAC receptors with TPMPA (60
mM). A, The IPSC remaining in the presence of TPMPA is effectively
inhibited by 10 mM bicuculline. B, The GABAA receptor-mediated IPSC
is positively modulated by benzodiazepines. Flurazepam had no effect on
peak amplitude but increased the half width by 121 6 5%.
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by the anesthetic propofol or by the barbiturate pentobarbitone,
agents that potentiate the response to GABA at GABAA recep-
tors. However, unlike GABAC receptors, the BIC-resistant re-
sponse is inhibited by the benzodiazepines diazepam and
flurazepam.
BIC is a competitive antagonist of GABA, and it is possible
that the “BIC-resistant” response simply represents the current
caused by activation of GABA receptors as BIC unbinds in the
presence of GABA. This is unlikely for several reasons. (1) The
GABA response resistant to BIC had a pharmacological profile
different to that of GABAA receptors. (2) If BIC was being
competed off, we would expect that the response in the presence
of BIC would have a slower rising phase than the control re-
sponse. However, neither the iontophoretic response to GABA
nor the synaptic current remaining in BIC had slower rising
phases. (3) If BIC was unbinding, then we would expect that the
fractional block of the synaptic current by BIC would be signifi-
cantly higher than during iontophoresis because GABA will be
present for a much shorter duration when it is released synapti-
cally (Clements, 1996). However, the fractional block of the
GABA response during iontophoretic application of GABA was
very similar to that of the synaptic current (34 vs 33%). (4) The
much higher affinity antagonist SR95531 also revealed two types
of GABA response. Thus, we are confident that the BIC-resistant
response represents activation of a different type of GABA
receptor.
GABAC receptors were first found in the retina where they
have been extensively characterized in a number of species in
bipolar and horizontal cells (Bormann and Feigenspan, 1995).
These receptors are thought to be assembled from r subunits of
which three genes, r1, r2, and r3 have been found (Cutting et al.,
1991; Shimada et al., 1992). Homomeric r1 receptors are suffi-
cient to form ion channels with properties consistent with those of
GABAC receptors. However, r1 and r2 can also assemble as
heterooligomers with properties different from those of homo-
meric channels (Enz and Cutting, 1999), raising the possibility of
some diversity in GABAC receptors. Although r subunits have
been detected in brain (Enz et al., 1995; Boue-Grabot et al., 1998;
Enz and Cutting, 1999), and BIC-resistant responses to GABA
have also been reported (Drew et al., 1984; Arakawa and Okada,
1988; Strata and Cherubini, 1994), the presence of GABAC
receptors in central neurons has not been clearly demonstrated
(Johnston, 1996b). Our results suggest the presence of a GABAC-
like receptor in the central amygdala. It is not known whether
neurons in the CeL express r subunits. However, it is unlikely that
the BIC-insensitive responses we have recorded are caused by
receptors assembled from r subunits alone as such receptors, like
GABAC receptors, are unaffected by bicuculline and benzodiaz-
epines (Bormann and Feigenspan, 1995), whereas the BIC-
resistant response the CeL is blocked by high concentrations of
BIC and is negatively modulated by benzodiazepines.
GABAA receptors are assembled from 15 different subunits.
These subunits can form functional channels as homomers or as
heteromultimers of various subunit combinations. However, a, b,
and g subunits are required to reproduce the full pharmacological
profile of native GABA receptors. Both a and g subunits deter-
mine benzodiazepine sensitivity. The responses of receptors con-
taining g subunits are amplified by benzodiazepines, whereas
receptors lacking g subunits are insensitive to benzodiazepines.
Receptors containing and a6 subunits are also benzodiazepine-
insensitive (Costa, 1998). In situ hybridization studies have shown
that a1, a2, a3, b1, b2, b3, g1, g2, and g3 subunits are expressed
in the central amygdala (Wisden et al., 1992). Thus, subunits that
could produce GABA receptors positively modulated by benzo-
diazepines are present, consistent with the presence of such
receptors on CeL neurons. Although inverse agonists of GABA
receptors are known, no GABA receptor examined so far has
been found to be negatively modulated by the 1,4 benzodiaz-
epines (Costa, 1998). The presence of the g1 subunit is known to
produce atypical benzodiazepine pharmacology turning the in-
verse agonist Ro15–4513 into an agonist (Wafford et al., 1993).
Furthermore, small changes in the primary structure of receptor
subunits can dramatically change the pharmacological profile of
that receptor (Wang et al., 1995; Valfa and Schofield, 1998).
Thus, one possibility is that the receptors we have characterized
here are assembled from variants of known GABAA receptor
subunits. Alternatively, it is not inconceivable that an as yet
undiscovered subunit might confer the unusual benzodiazepine
pharmacology in CeL neurons. The fact that the effect of benzo-
diazepines was inhibited by Ro 15–1788 suggests that the binding
site for these agents on GABAC-like receptors might be the same
as in other, positively modulated GABAA receptors.
The amygdala is a key structure in the processing of emotional
information (LeDoux, 1996) and has been implicated in the
genesis of fear responses. Dysfunction of the amygdala has been
suggested to underlie anxiety-type disorders (Davis, 1992; Le-
Doux, 1995). The benzodiazepines, which are widely used in the
treatment of such disorders, are thought to act by enhancing the
actions of GABA at GABAA receptors (Tallman and Gallager,
1985; Costa and Guidotti, 1996). The presence of a GABA
receptor in the amygdala that is inhibited by benzodiazepines
suggests that the actions of these agents in the amygdala are more
complex than previously thought. This receptor might be a pos-
sible new target in the development of therapeutic agents for
disorders involving the amygdala.
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